Arkolith/Insider Trading/PHIO/Form 4

Bitterman Robert J

Chairman, Pres & CEO, DirectorPhio Pharmaceuticals Corp. (PHIO) · full profile →Form 4 · filed Jun 11, 2025
Net Buying
Open-Market Buys
$5K
Open-Market Sells
$0
Net Open-Market Flow
$5K
Transactions
1
1 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jun 10, 2025Buy(P)2K$2.42$5K27K

Transaction Codes

P
Open-market purchase

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001062993-25-011424) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML